Skip to main content
Clinical Trials/DRKS00024134
DRKS00024134
Completed
未知

Prospective evaluation of the DEtection rate of clinically significant PROstate cancer by mpMRI and PSMA-PET/CT fusion biopsy - DEPROMP

Klinik und Poliklinik für Urologie und Kinderurologie Universitätsklinikum Bonn0 sites246 target enrollmentJanuary 26, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Prostate cancer
Sponsor
Klinik und Poliklinik für Urologie und Kinderurologie Universitätsklinikum Bonn
Enrollment
246
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 26, 2021
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Klinik und Poliklinik für Urologie und Kinderurologie Universitätsklinikum Bonn

Eligibility Criteria

Inclusion Criteria

  • The patient is suspected of having a localised prostate carcinoma based on at least one of the following criteria, so that clarification by means of MRI fusion punch biopsy is indicated:
  • PSA\-value \= 4 ng/ml or
  • suspicious tactile findings of the prostate in the digital rectal examination or
  • suspicious findings in transrectal sonography
  • patients must be \= 45 years and \< 76 years old
  • patients must be biopsy\-naive
  • patient gives documented written consent to participate in the study
  • patients who are able to follow the study instructions and who are likely to adhere to all required study visits (compliance)

Exclusion Criteria

  • The patient has a PSA level elevation of \>100 ng/ml with resulting suspicion of advanced metastatic prostate carcinoma
  • The patient has a serious kidney disease, defined by Estimated creatinine clearance \< 30 ml/min (using a site\-specific method)

Outcomes

Primary Outcomes

Not specified

Similar Trials